title: Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment.
abstract: Recent studies have shown that cytokine treatment of tumor cells alters the sensitivity of these cells to lymphokine-activated killer (LAK) cells, depending on the cell line. In this study, we analyzed the decrease in LAK sensitivity of a human renal-cell carcinoma cell line (SMKT-R-3). The LAK sensitivity of SMKT-R-3 was decreased by treatment with a combination of interferon gamma (IFN gamma) and tumor necrosis factor (TNF). However, the cytokine treatment increased the expression of intercellular adhesion molecule-1 (ICAM-1) on the renal-cell carcinoma cell surface. The conjugate-formation assay also confirmed a slight increase in the binding rate of LAK cells to the renal-cell carcinoma cells. When actinomycin D (a protein synthesis inhibitor) was added to the culture medium prior to treatment with IFN gamma and TNF, the LAK sensitivity of SMKT-R-3 recovered to the level demonstrated by the cells that had not received any cytokine treatment. These results suggest that the effect of cytokines in reducing LAK sensitivity of SMKT-R-3 is mediated by protein synthesis occurring when LAK cells are bound to SMKT-R-3 cells.
authors.affiliation: Department of Urology, Sapporo Medical University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yanase
authors.forename: T
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kumamoto
authors.forename: K
authors.initials: K
authors.lastname: Kato
authors.forename: Y
authors.initials: Y
authors.lastname: Hashimoto
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D015815:Cell Adhesion Molecules / Q000032:analysis; D002450:Cell Communication / Q000502:physiology; D003131:Combined Modality Therapy; D003609:Dactinomycin / Q000494:pharmacology; D006801:Humans; D016219:Immunotherapy, Adoptive; D018799:Intercellular Adhesion Molecule-1; D007371:Interferon-gamma / Q000008:administration & dosage / Q000494:pharmacology*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000166:cytology / Q000187:drug effects; D011994:Recombinant Proteins; D012680:Sensitivity and Specificity; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D015815:Cell Adhesion Molecules; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D018799:Intercellular Adhesion Molecule-1; D003609:Dactinomycin; D007371:Interferon-gamma